Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 118875
1. Baten E, van Renterghem K: The Advantages of Transurethral Resection of the Prostate in Patients with an Elevated or Rising Prostate Specific Antigen, Mild or Moderate Lower Urinary Tract Symptoms, Bladder Outlet Obstruction and Negative Prostate Cancer Imaging or Prostate Biopsies: A Prospective Analysis in 105 Consecutive Patients. Curr Urol; 2017 Aug;10(3):140-144
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Advantages of Transurethral Resection of the Prostate in Patients with an Elevated or Rising Prostate Specific Antigen, Mild or Moderate Lower Urinary Tract Symptoms, Bladder Outlet Obstruction and Negative Prostate Cancer Imaging or Prostate Biopsies: A Prospective Analysis in 105 Consecutive Patients.
  • OBJECTIVE: To investigate elevated or rising prostate specific antigen (PSA) as a marker for bladder outlet obstruction (BOO) in patients with minor lower urinary tract symptoms (LUTS) and without prostate cancer.
  • Only patients with minor LUTS [International Prostate Symptom Score (I-PSS) 0-19] and without suspicion for prostate cancer were included.
  • All patients had BOO, shown by full urodynamics, and underwent transurethral resection of the prostate.
  • The mean detrusor pressure at maximum flow was 93.6 cmH<sub>2</sub>O.
  • The mean resected volume was 52 g and the mean prostate biopsy rate was 1.8.
  • Eighty-three of 105 patients (79%) had no malignancy and were diagnosed with BOO due to benign prostate hyperplasia (subgroup 1).
  • Sixteen of 105 patients (15%) were treated for prostate cancer (subgroup 2).
  • CONCLUSION: BOO can cause an elevated or rising PSA in patients with minor LUTS and negative screening for prostate cancer.
  • Transurethral resection of the prostate is an adequate treatment for these patients.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Nov 10;23(32):8152-60 [16278466.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):234-9 [10344212.001]
  • [Cites] Eur Urol. 2008 Dec;54(6):1385-92 [18599187.001]
  • [Cites] Urol Oncol. 2016 Jul;34(7):296-302 [26725249.001]
  • [Cites] Eur Urol. 2011 Jan;59(1):61-71 [21056534.001]
  • [Cites] Urology. 2007 Feb;69(2):215-20 [17320653.001]
  • [Cites] Clin Genitourin Cancer. 2015 Dec;13(6):512-7 [26231912.001]
  • [Cites] J Urol. 2005 Mar;173(3):691-6 [15711245.001]
  • [Cites] Curr Opin Urol. 2016 Jan;26(1):22-7 [26555691.001]
  • [Cites] Prog Urol. 2016 Feb;26(2):129-36 [26643518.001]
  • (PMID = 28878597.001).
  • [ISSN] 1661-7649
  • [Journal-full-title] Current urology
  • [ISO-abbreviation] Curr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Bladder outlet obstruction / PdetQmax / Prostate Specific Antigen / Prostate cancer / Transurethral Resection of the Prostate
  •  go-up   go-down


2. Paydar I, Pepin A, Cyr RA, King J, Yung TM, Bullock EG, Lei S, Satinsky A, Harter KW, Suy S, Dritschilo A, Lynch JH, Kole TP, Collins SP: Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity. Front Oncol; 2017;7:5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.
  • BACKGROUND: Recent data suggest that intensity-modulated radiation therapy (IMRT) plus brachytherapy boost for unfavorable prostate cancer provides improved biochemical relapse-free survival over IMRT alone.
  • MATERIALS AND METHODS: Between March 2008 and September 2012, patients with prostate cancer were treated with robotic SBRT (19.5 Gy in three fractions) followed by fiducial-guided IMRT (45-50.4 Gy) on an institutional protocol.
  • Toxicity was prospectively graded using the common terminology criteria for adverse events version 4.0 (CTCAEv.4) at the start of and at 1- to 6-month intervals after therapy.
  • Future studies should compare cancer control, quality of life, and toxicity with other treatment modalities for patients with high-risk prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Technol Cancer Res Treat. 2010 Oct;9(5):453-62 [20815416.001]
  • [Cites] Front Oncol. 2016 May 06;6:114 [27200300.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):150-4 [16111583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):937-9 [26530768.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):285-95 [9572622.001]
  • [Cites] J Urol. 2015 Dec;194(6):1624-30 [26165583.001]
  • [Cites] Radiat Oncol. 2016 Jan 21;11:8 [26792201.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9 [22330997.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):751-8 [20207506.001]
  • [Cites] Technol Cancer Res Treat. 2010 Dec;9(6):575-82 [21070079.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1192-9 [15718316.001]
  • [Cites] Radiother Oncol. 2012 Jul;104(1):114-8 [22727264.001]
  • [Cites] Radiat Oncol. 2013 Mar 13;8:58 [23497695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55 [15001244.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):1990-6 [16648499.001]
  • [Cites] Urology. 2000 Dec 20;56(6):899-905 [11113727.001]
  • [Cites] Acta Oncol. 2005;44(3):265-76 [16076699.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):316-27 [12023135.001]
  • [Cites] Cancer. 2015 Jul 15;121(14):2422-30 [25847819.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):999-1007 [16750320.001]
  • [Cites] Urology. 2000 Mar;55(3):382-6 [10699615.001]
  • [Cites] Radiat Oncol. 2013 Jan 31;8:30 [23369294.001]
  • [Cites] Radiother Oncol. 2012 May;103(2):217-22 [22341794.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82 [21300474.001]
  • [Cites] Cancer. 2013 Feb 1;119(3):681-90 [22893254.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):383-7 [18947938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74 [17765406.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2630-7 [10375112.001]
  • [Cites] J Urol. 2016 Jun;195(6):1811-6 [26778712.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):679-85 [22954770.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1443-53 [27325475.001]
  • [Cites] Radiother Oncol. 2000 Jan;54(1):11-9 [10719695.001]
  • [Cites] Radiat Oncol. 2014 Jan 01;9:1 [24382205.001]
  • [Cites] Br J Radiol. 2015 Oct;88(1054):20140736 [26235142.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Aug 1;92 (5):971-7 [26054865.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):932-8 [24113055.001]
  • [Cites] Front Oncol. 2014 Oct 31;4:278 [25401085.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 2):S21-5; discussion S26-7 [14610406.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55 [17531401.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1306-16 [15817332.001]
  • [Cites] Radiat Oncol. 2014 Dec 12;9:277 [25497602.001]
  • [Cites] Radiother Oncol. 2009 May;91(2):232-6 [19097660.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5366-73 [18048817.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1233-9 [16160131.001]
  • [Cites] Front Oncol. 2015 Sep 01;5:194 [26389077.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):184-91 [12694837.001]
  • [Cites] J Urol. 2007 Jan;177(1):123-7; discussion 127 [17162020.001]
  • (PMID = 28224113.001).
  • [ISSN] 2234-943X
  • [Journal-full-title] Frontiers in oncology
  • [ISO-abbreviation] Front Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; CyberKnife / IMRT / SBRT / common terminology criteria / prostate cancer
  •  go-up   go-down


3. Tanaka N, Asakawa I, Nakai Y, Miyake M, Anai S, Fujii T, Hasegawa M, Konishi N, Fujimoto K: Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer. BMC Cancer; 2017 Aug 25;17(1):573
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
  • BACKGROUND: To compare the PSA value at the last follow-up of patients who underwent prostate low-dose rate brachytherapy (LDR-BT) with that of patients who underwent intensity-modulated radiation therapy (IMRT).
  • METHODS: A total of 610 prostate cancer patients (cT1c-3bN0M0) were enrolled, and 445 of them underwent LDR-BT, while 165 received IMRT (74-76 Gy).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2014 Sep;114(3):360-7 [24447404.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):87-93 [24331654.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):36-42 [19409729.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1336-42 [20605342.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):527-33 [16242258.001]
  • [Cites] J Urol. 2013 Mar;189(3):878-83 [23103235.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):528-34 [11792912.001]
  • [Cites] Radiat Oncol. 2014 May 06;9:107 [24885896.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):600-7 [21985944.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):57-64 [17084544.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1310-7 [20493642.001]
  • [Cites] J Urol. 2003 Feb;169(2):517-23 [12544300.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):355-60 [19632069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2017 Jun 1;98 (2):275-285 [28262473.001]
  • [Cites] Urology. 2011 Apr;77(4):986-90 [21195465.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74 [16798415.001]
  • [Cites] Int J Urol. 2009 Jan;16(1):70-4 [19120529.001]
  • [Cites] BJU Int. 2012 Feb;109 Suppl 1:22-9 [22239226.001]
  • [Cites] JAMA. 1998 Sep 16;280(11):969-74 [9749478.001]
  • (PMID = 28841855.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; BED / Biochemical recurrence-free rate / IMRT / Low-dose rate brachytherapy / Prostate cancer / Testosterone
  •  go-up   go-down


Advertisement
4. Hosni A, Rosewall T, Craig T, Kong V, Bayley A, Berlin A, Bristow R, Catton C, Warde P, Chung P: The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. Radiat Oncol; 2017 Mar 09;12(1):50
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer.
  • BACKGROUND: This study aimed to investigate the tolerability and impact of milk of magnesia (MoM) on interfraction rectal filling during prostate cancer radiotherapy.
  • METHODS: Two groups were retrospectively identified, each consisting of 40 patients with prostate cancer treated with radiotherapy to prostate+/-seminal vesicles, with daily image-guidance in 78Gy/39fractions/8 weeks.
  • [MeSH-major] Artifacts. Intestine, Small / physiology. Prostatic Neoplasms / radiotherapy. Radiotherapy, Image-Guided / methods

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1611-21 [15590193.001]
  • [Cites] Eur Urol. 2011 Dec;60(6):1133-9 [21889832.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9 [22330997.001]
  • [Cites] Radiother Oncol. 2010 Jun;95(3):277-82 [20451274.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72 (2):456-66 [18374517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1072-8 [19783378.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):548-53 [16545919.001]
  • [Cites] Strahlenther Onkol. 2014 Aug;190(8):758-61 [24760248.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):525-33 [10348281.001]
  • [Cites] Radiother Oncol. 2011 Dec;101(3):471-8 [21903283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):646-50 [24054874.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1418-24 [17241751.001]
  • [Cites] Radiother Oncol. 1999 Feb;50(2):225-34 [10368047.001]
  • [Cites] Jpn J Radiol. 2009 Jun;27(5):205-12 [19554413.001]
  • [Cites] JAMA. 1997 May 14;277(18):1445-51 [9145716.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1279-86 [18572088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):965-73 [15989996.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1405-18 [19616743.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):653-60 [22099039.001]
  • [Cites] Acta Oncol. 2014 Apr;53(4):569-71 [24237391.001]
  • (PMID = 28279179.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Laxatives
  • [Keywords] NOTNLM ; Bowel preparation / Laxative / Prostate cancer / Radiotherapy / Rectum
  •  go-up   go-down


5. Treutwein M, Hipp M, Koelbl O, Dobler B: Volumetric-modulated arc therapy and intensity-modulated radiation therapy treatment planning for prostate cancer with flattened beam and flattening filter free linear accelerators. J Appl Clin Med Phys; 2017 Sep;18(5):307-314

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volumetric-modulated arc therapy and intensity-modulated radiation therapy treatment planning for prostate cancer with flattened beam and flattening filter free linear accelerators.
  • This study on patients with localized prostate cancer was set up to investigate valuable differences using flattened beam (FB) and flattening filter free (FFF) mode in the application of intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT).
  • VMAT-FFF combines the most advantageous plan quality parameters with the shortest delivery times and reduced peripheral dose and is therefore recommended for the given equipment and cancer localization.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.
  • (PMID = 28857432.001).
  • [ISSN] 1526-9914
  • [Journal-full-title] Journal of applied clinical medical physics
  • [ISO-abbreviation] J Appl Clin Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; IMRT / VMAT / flattening filter free / prostate cancer
  •  go-up   go-down


6. Cagney DN, Dunne M, O'Shea C, Finn M, Noone E, Sheehan M, McDonagh L, O'Sullivan L, Thirion P, Armstrong J: Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy. BMC Urol; 2017 Aug 01;17(1):60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy.
  • BACKGROUND: Our aim was to assess the heterogeneity of high-risk (HR) prostate cancer managed with high-dose external beam radiotherapy (EBRT) with androgen deprivation therapy (ADT).
  • On multivariate analysis, significant predictors of shorter bRFS were biopsy Gleason score (bGS) of 8 to 10, higher prostate-specific antigen (PSA) level, shorter duration of ADT and lower radiation dose while predictors of shorter DMFS were bGS of 8 to 10, higher PSA level, and lower radiation dose.
  • We identified an unfavorable high-risk (UHR) group of with 2-3 HR factors based on 2015 National Comprehensive Cancer Network (NCCN) criteria and a favorable high-risk (FHR) group, with 1 HR feature.
  • Comparing very-HR prostate cancer, UHR & FHR, 5 year bRFS rates were 58.2%, 66.2%, and 69.2%, and 5 year DMFS rates were 78.4%, 81.2%, and 88.0%.
  • Future studies should account for this heterogeneity in HR prostate cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):609-15 [10837943.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):103-6 [12126818.001]
  • [Cites] J Urol. 2005 Jun;173(6):1938-42 [15879786.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2597-603 [17039498.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):980-8 [18495377.001]
  • [Cites] J Urol. 2007 Jun;177(6):2106-31 [17509297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1397-404 [21665379.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):254-62 [26853334.001]
  • [Cites] Eur Urol. 2010 Jul;58(1):1-7; discussion 10-1 [20299147.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):125-30 [19695789.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 2):S16-20 [17084158.001]
  • [Cites] N Engl J Med. 2009 Jun 11;360(24):2516-27 [19516032.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74 [17765406.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2014 Mar;17(1):57-63 [24189998.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):330-7 [18164858.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2497-504 [18413638.001]
  • [Cites] JAMA. 2004 Aug 18;292(7):821-7 [15315996.001]
  • [Cites] Cancer. 2009 Jul 1;115(13 Suppl):3112-20 [19544539.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):828-35 [26530751.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74 [16798415.001]
  • [Cites] Lancet Oncol. 2007 Jun;8(6):475-87 [17482880.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90 [15817329.001]
  • [Cites] BJU Int. 2011 Mar;107(5):765-770 [20875089.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1028-33 [18280056.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1233-9 [16160131.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1419-23 [19131185.001]
  • [Cites] J Clin Oncol. 2015 Apr 20;33(12 ):1356-63 [25624432.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1141-8 [22099043.001]
  • [Cites] JAMA. 1998 Sep 16;280(11):969-74 [9749478.001]
  • (PMID = 28764689.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Bell LJ, Eade T, Kneebone A, Hruby G, Alfieri F, Bromley R, Grimberg K, Barnes M, Booth JT: Initial experience with intra-fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment. J Med Radiat Sci; 2017 Mar;64(1):25-34
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial experience with intra-fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment.
  • INTRODUCTION: Accurate delivery of radiation while reducing dose to organs at risk is essential in prostate treatment.
  • Three patients had Calypso beacons inserted into their prostate.
  • Prostate rotation was largest in the pitch direction and 28 fractions exceeded the 10° tolerance.
  • [MeSH-major] Dose Fractionation. Movement. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. Journal of Medical Radiation Sciences published by Wiley Publishing Asia Pty Ltd on behalf of Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology.
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1579-85 [20472357.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1099-105 [17336216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1088-98 [17187940.001]
  • [Cites] Med Phys. 2014 Feb;41(2):020702 [24506591.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1017-25 [25832692.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):477-83 [23523325.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105 [12128107.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):51-63 [12504036.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):528-34 [16690435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):682-9 [17398026.001]
  • (PMID = 28263041.001).
  • [ISSN] 2051-3909
  • [Journal-full-title] Journal of medical radiation sciences
  • [ISO-abbreviation] J Med Radiat Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; calypso / implementation / intra-fraction motion / prostate / radiation treatment
  •  go-up   go-down


8. Javanmard B, Hassanzadeh Haddad A, Yaghoobi M, Lotfi B: Diode laser ablation of prostate and channel transurethral resection of prostate in patients with prostate cancer and bladder outlet obstruction symptoms. Urol J; 2014 Jul-Aug;11(4):1788-92
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diode laser ablation of prostate and channel transurethral resection of prostate in patients with prostate cancer and bladder outlet obstruction symptoms.
  • PURPOSE: To evaluate the efficacy of diode laser ablation of prostate for treating lower urinary tract symptoms (LUTS) in patients with locally advanced prostate cancer and comparing results with palli­ative transurethral resection of prostate (pTURP).
  • MATERIALS AND METHODS: Thirty-six known cases of locally advanced prostate cancer with a maximum urinary flow rate (Qmax) of 12 mL per second or less and an International Prostate Symptom Score (IPSS) of 20 or more were included in this study.
  • The first group underwent pTURP and for the second group diode laser ablation of prostate was done.
  • CONCLUSION: Diode laser ablation of prostate and pTURP, both improved significantly IPSS, PVR and Qmax.
  • [MeSH-major] Ablation Techniques / instrumentation. Carcinoma / surgery. Lasers, Semiconductor / therapeutic use. Palliative Care. Prostatic Neoplasms / surgery. Prostatism / surgery. Urinary Bladder Neck Obstruction / surgery
  • [MeSH-minor] Aged. Humans. Length of Stay. Male. Middle Aged. Operative Time. Time Factors. Transurethral Resection of Prostate. Urinary Catheterization. Urodynamics

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25194077.001).
  • [ISSN] 1735-546X
  • [Journal-full-title] Urology journal
  • [ISO-abbreviation] Urol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Iran
  •  go-up   go-down


9. Schally AV, Block NL, Rick FG: Discovery of LHRH and development of LHRH analogs for prostate cancer treatment. Prostate; 2017 Jun;77(9):1036-1054
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.
  • The design, synthesis, and experimental and clinical testing of agonistic analogs of LHRH is extensively reviewed focusing on the development of new methods for the treatment of prostate cancer.
  • Subsequent development of antagonistic analogs of LHRH is then faithfully recounted with special emphasis on therapy of prostate cancer and BPH.
  • The endeavor to develop better therapies for prostate cancer, based on LHRH analogs, guided much of our work.
  • [MeSH-major] Gonadotropin-Releasing Hormone. Prostatic Neoplasms
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Humans. Male. Medication Therapy Management. Molecular Targeted Therapy / methods. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28449236.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Keywords] NOTNLM ; CRPC / advanced prostate cancer / androgen deprivation therapy / luteinizing hormone-releasing hormone / targeted therapy
  •  go-up   go-down


10. Skácelíková E, Feltl D, Cvek J, Jelenová T, Knybel L, Tomášková H: [Stereotactic Body Radiotherapy of Prostate Cancer - Effectiveness and Toxicity]. Klin Onkol; Spring 2017;30(2):121-127
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stereotactic Body Radiotherapy of Prostate Cancer - Effectiveness and Toxicity].
  • [Transliterated title] Stereotaktická radioterapie karcinomu prostaty - efektivita a toxicita.
  • BACKGROUND: Prostate cancer is the most prevalent cancer in males and its incidence is steadily increasing.
  • Most cases of prostate cancer are diagnosed during the early asymptomatic period, in which case the prognosis is very good.
  • One treatment method for early stage prostate cancer is stereotactic body radiotherapy (SBRT).
  • PATIENTS AND METHODS: A total of 261 patients with low or intermediate risk prostate cancer were treated with SBRT between August 2010 and July 2012.
  • For assessment of quality of life, patients filled out a modified EPIC questionnaire (Expanded Prostate Composite index).
  • CONCLUSION: SBRT is an effective therapeutic modality for early prostate cancer and has acceptable rates of acute and low late toxicity.Key words: prostate cancer - stereotactic body radiotherapy - quality of life The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
  • [MeSH-major] Prostatic Neoplasms / radiotherapy. Quality of Life. Radiosurgery / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28397507.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down






Advertisement